NCT01441232

A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 Diabetics

A Phase 1, Open-label, 3-period, 3-treatment, Single Dose Crossover Study to Evaluate the Pharmacodynamic Effects of LX4211 When Administered Concurrently With JANUVIA® (Sitagliptin) in Subjects With Type 2 Diabetes Mellitus

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: Lexicon Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study is intended to evaluate the pharmacodynamics, safety, and tolerability of LX4211 when administered concurrently with sitagliptin (Januvia®) in patients with Type 2 Diabetes Mellitus.

Conditions

• Type 2 Diabetes Mellitus

Interventions

Type	Name	Description
DRUG	LX4211	400 mg of LX4211 administered as two 200 mg tablets
DRUG	Januvia®	100 mg Januvia® (sitagliptin) administered as one 100 mg sitagliptin tablet

Timeline

• Start date: 2011-10-01
• Primary completion: 2011-11-01
• First posted: 2011-09-27
• Last updated: 2012-01-31

Locations

1 site across 1 country: United States